Press Releases

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received approvals from the U.S. Food and Drug Administration for Abbreviated New Drug Applications referencing GlaxoSmithKline's...

Perrigo Company plc (NYSE: PRGO; TASE) today announced its intention to restructure the Branded Consumer Healthcare's ("BCH") Omega Pharma Belgium business (which includes Omega Pharma Belgium NV,...

Delivered third quarter GAAP ("reported") net sales of $1.4 billion and non-GAAP ("adjusted") net sales of $1.3 billion, excluding sales of $22 million from held-for-sale businesses* Delivered...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream...

Perrigo Company plc (NYSE: PRGO; TASE) today announced the appointment of independent Directors Geoffrey M. Parker and Theodore R. Samuels to its Board of Directors, further enhancing its...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on December 13, 2016 to shareholders of record on...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its third quarter calendar year 2016 on Thursday, November 10, 2016 at approximately 6:30 a.m....

Perrigo Company plc (NYSE: PRGO; TASE) today announced an exclusive licensing agreement with Highland Pharmaceuticals, LLC for its Tarex® methamphetamine ("meth") blocking technology and the...

Perrigo Company plc (NYSE: PRGO; TASE) today acknowledged receipt of a letter from Starboard Value LP, a Perrigo shareholder. Perrigo will review the letter carefully and looks forward to a...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chief Executive Officer John T. Hendrickson will present at the Morgan Stanley Global Healthcare Conference at 11:05 AM EDT on...